Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanoViricides, Inc. Announces That It Has Submitted a Pre-IND Meeting Request to the US FDA For Its Anti-Influenza Clinical Drug Candidate, FluCide™: Submission Represents a Major Advance for the Company

Abstract:
NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has submitted a pre-IND Meeting Request to the US FDA. The Company has requested an initial meeting with the US FDA to review the Company's proposed strategy and plan for conducting safety/toxicology studies and human clinical trials required for approval of its anti-influenza clinical drug candidate, FluCide™ (i.e. NV-INF-1).

NanoViricides, Inc. Announces That It Has Submitted a Pre-IND Meeting Request to the US FDA For Its Anti-Influenza Clinical Drug Candidate, FluCide™: Submission Represents a Major Advance for the Company

West Haven, CT | Posted on December 6th, 2011

"This submission is a major milestone in the Company's program to obtain US FDA approval for FluCide™," said Eugene Seymour, MD, MPH, CEO, adding, "FluCide has demonstrated excellent efficacy and safety when treating influenza infections in our animal studies. We anticipate similar strong results in humans when the drug becomes available for human use."

The Company has submitted required introductory documentation with the meeting request letter in consultation with the Company's regulatory matters consultants, viz. the Biologics Consulting Group. The Company plans to submit additional briefing documents at least thirty days before the FDA meeting, in compliance with the FDA guidelines.

This pre-IND meeting request submission follows the Company's recent announcement that it has chosen a clinical candidate, NV-INF-1, in its anti-influenza drug program (FluCide™) to develop for regulatory submissions both domestically and internationally. It is estimated that there are about 50 million cases of influenza annually in the USA alone, and about 250,000 patients are hospitalized for influenza. The Company believes that a single course of therapy that can be easily administered by a medical office is likely to be feasible for out-patients, with no additional follow-on treatment necessary. This expectation is based on the following results from its animal studies: (1) the extremely high treatment effectiveness in inhibiting the cycle of infection, virus expansion and spread of infection and, (2) the significantly long lasting effects of the drug treatment after the drug is discontinued. In addition to out-patients, the Company also plans to develop an indication for hospitalized severe cases of influenza.

The Company has recently announced that it is working on developing cGMP ("current Good Manufacturing Practices") manufacturing capability for the production of its drug candidates. cGMP manufactured materials will be required when the Company is ready to file an Investigational New Drug (IND) application to the US FDA.

####

About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Dengue fever, Hepatitis C, Rabies, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon, 310-550-7200

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Elliot Scientific now representing Raman Imaging specialists WITec in the UK and Eire - Unique correlative analysis in one instrument: Raman/AFM, Raman/SNOM December 10th, 2018

A new 'spin' on kagome lattices: Team's findings shed new light on the presence of spin-orbit coupling and topological spin textures in kagome lattices December 9th, 2018

Milestone for bERLinPro: Photocathodes with high quantum efficiency December 8th, 2018

Harnessing the power of 'spin orbit' coupling in silicon: Scaling up quantum computation December 7th, 2018

Govt.-Legislation/Regulation/Funding/Policy

A new 'spin' on kagome lattices: Team's findings shed new light on the presence of spin-orbit coupling and topological spin textures in kagome lattices December 9th, 2018

It's not a shock: Better bandage promotes powerful healing November 29th, 2018

French Researchers Extend Reach of Mass Spectrometry with Nanomechanical Resonators: Neutral Mass Spectrometry’ Fills Gap In Existing Weighing Technologies November 27th, 2018

Three CEA Projects Awarded European Research Council Synergy Grants November 26th, 2018

Nanomedicine

A*STAR, One BioMed launch S$9m joint lab to make diagnostic kit for infectious diseases December 3rd, 2018

New research could fine-tune the gene scissors CRISPR December 1st, 2018

It's not a shock: Better bandage promotes powerful healing November 29th, 2018

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results November 27th, 2018

Announcements

Elliot Scientific now representing Raman Imaging specialists WITec in the UK and Eire - Unique correlative analysis in one instrument: Raman/AFM, Raman/SNOM December 10th, 2018

A new 'spin' on kagome lattices: Team's findings shed new light on the presence of spin-orbit coupling and topological spin textures in kagome lattices December 9th, 2018

Milestone for bERLinPro: Photocathodes with high quantum efficiency December 8th, 2018

Harnessing the power of 'spin orbit' coupling in silicon: Scaling up quantum computation December 7th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project